Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/12/21
Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/11/21
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive LymphomasGlobeNewsWire • 07/13/21
Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann's Virtual 2021 Healthcare ConferenceGlobeNewsWire • 07/07/21
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/13/21
Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business UpdateGlobeNewsWire • 05/05/21
Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionGlobeNewsWire • 03/16/21
Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common StockGlobeNewsWire • 03/12/21
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital ConferenceGlobeNewsWire • 02/10/21
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021GlobeNewsWire • 01/11/21
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/12/20
Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020GlobeNewsWire • 10/26/20
Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical OfficerGlobeNewsWire • 10/23/20
Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth ConferenceGlobeNewsWire • 10/05/20
Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020GlobeNewsWire • 09/21/20
Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in CancerGlobeNewsWire • 07/13/20